ACE: From Community Stories to Enterprise Intelligence

Health systems and research partners need rich, culturally grounded community insight to design better outreach, recruitment, and care delivery. Raw community stories carry that insight, but they are hard to aggregate, compare, or act on at enterprise scale.

The product challenge was preserving the human voice while translating it into structured intelligence — for enterprise buyers on one side and for the community members whose stories are the asset on the other. ACE exists to close the gap between what communities say and what enterprises hear.

Acclinate already held something rare: community stories gathered with trust, through NOWINCLUDED and the community teams. The product opportunity was to make that narrative easier for enterprise teams to interpret and act on without stripping away its meaning.

I proposed three target buyer segments and their jobs to be done to make the concept more specific than one generic "insights" pitch. I do not present those segments as validated because I do not have a verified buyer-conversation count or supporting discovery evidence to publish.

The community side of discovery set the harder boundary: any use of these stories has to survive the question of whether the person who told it would recognize and accept what was done with it.

Defined the core value proposition and three target segments: Patient Science / Population Health, Clinical Operations / Trial Strategy, and Medical Affairs / Commercial. These made the product direction specific, but early commercial activity does not establish that all three segments were validated.

Authored the product companion document, MVP direction, and interpretation guardrails. Those materials set requirements and boundaries around consent, de-identification, source traceability, bias review, human review, and unsupported inference; the available records do not confirm that each control was technically enforced in the demo.

David Faulk built the ACE Health Equity World Model. I owned the product definition around that work; I did not personally train the model or implement the AI infrastructure. The records do not confirm a model provider, retrieval architecture, source corpus, or access-control implementation, so I do not name them.

The cross-functional team moved the concept from written definition to a working enterprise demo in roughly 80 days. It was demonstrated externally to a biopharma stakeholder in December 2025, and a stable demo link was recorded by January 7, 2026.

AI fit this problem for a specific reason: the work is turning a large volume of unstructured, spoken human language into comparable themes. That is a language problem at a scale people cannot do by hand. My product requirement was that outputs remain reviewable before informing a decision; the records do not establish that this review step was technically enforced in the demo.

Where AI was not appropriate was equally specific. Inference beyond what a story actually says — assigning clinical meaning, predicting behavior, or characterizing a community from thin evidence — is out of scope by design. The product summarizes and structures what people said; it does not decide what they meant.

The alternative was a services model: analysts reading stories and writing reports for each partner. That preserves nuance but does not scale in the same way. My recommendation was the product path with human review as a requirement, accepting slower trust-building in exchange for a potentially repeatable product.

The product requirement was more demanding than producing a polished summary: an output should preserve community meaning, trace back to source material, support a real enterprise decision, and remain reviewable by an accountable person.

Human review, consent, de-identification, source traceability, bias review, and limits on unsupported inference were documented requirements and boundaries. The available records do not confirm who reviewed outputs, how failures were handled, or whether every safeguard was implemented in the working demo.

I do not have a documented test set, reviewer roster, scoring thresholds, measured evaluation results, model benchmarks, or production outcomes to publish. Evaluation belongs here as a requirement and proposed approach, not as completed evidence.

Concept to a working enterprise demo in roughly 80 days, followed by an external biopharma demonstration in December 2025 and a stable demo link by January 7, 2026. This supports a demo used for early commercial discovery — not a production deployment, ongoing client access, internal pilot, or measured real-user adoption.

ACE appeared in an enterprise biopharma proposal/SOW with licensing language, an approximately $200K proposed scope expansion, and additional pipeline and account-planning activity. These are early commercial signals, not booked revenue, standalone willingness-to-pay evidence, or proof that all three target segments were validated.

The learning: responsible-use boundaries are part of the product definition, but their technical enforcement and effectiveness still have to be demonstrated before they can be claimed as implemented safeguards.

ACE opened an early commercial conversation about licensing structured community intelligence alongside the existing business, supported by an external demo, proposal language, and account-planning activity.

I led the product direction without claiming engineering implementation. The concept, name, product definition, product companion document, interpretation guardrails, target segments, MVP direction, and monetization thesis were mine; David Faulk built the World Model, and the broader team carried the demo and commercial work forward.